The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates

The global burden of disease caused by respiratory syncytial virus (RSV) is increasingly recognised, not only in infants, but also in older adults (aged ≥65 years). Advances in knowledge of the structural biology of the RSV surface fusion glycoprotein have revolutionised RSV vaccine development by p...

Full description

Saved in:

Bibliographic Details
Published in:	The Lancet infectious diseases Vol. 18; no. 10; pp. e295 - e311
Main Authors:	Mazur, Natalie I, Higgins, Deborah, Nunes, Marta C, Melero, José A, Langedijk, Annefleur C, Horsley, Nicole, Buchholz, Ursula J, Openshaw, Peter J, McLellan, Jason S, Englund, Janet A, Mejias, Asuncion, Karron, Ruth A, Simões, Eric AF, Knezevic, Ivana, Ramilo, Octavio, Piedra, Pedro A, Chu, Helen Y, Falsey, Ann R, Nair, Harish, Kragten-Tabatabaie, Leyla, Greenough, Anne, Baraldi, Eugenio, Papadopoulos, Nikolaos G, Vekemans, Johan, Polack, Fernando P, Powell, Mair, Satav, Ashish, Walsh, Edward E, Stein, Renato T, Graham, Barney S, Bont, Louis J
Format:	Journal Article
Language:	English
Published:	United States Elsevier Ltd 01.10.2018 Elsevier B.V Elsevier Limited
Subjects:	Adults Antibodies, Monoclonal - immunology Antibodies, Viral - immunology Antigens Candidates Children Clinical trials COVID-19 vaccines Disease prevention Global Health Glycoproteins Humans Immunoglobulins Immunology Infants Infections Infectious diseases Medical research Monoclonal antibodies Mutation Nanoparticles Older people Proteins Respiratory syncytial virus Respiratory Syncytial Virus Infections - prevention & control Respiratory Syncytial Virus Vaccines - immunology Vaccine development Vaccines Viruses World Health Organization United States > US
ISSN:	1473-3099, 1474-4457, 1474-4457
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!